10-Q: Ovid Therapeutics Reports Q2 2026 Financials

Ovid Therapeutics Inc. filed its Form 10-Q for the period ended June 30, 2026, detailing continued operating losses and a strong reliance on capital raises to fund its biopharmaceutical development.

Summary

• Ovid Therapeutics Inc. reported a net loss of $15.0 million for the three months ended June 30, 2026, and $32.0 million for the six months ended June 30, 2026.
• The company had $169.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026, which management believes is sufficient to fund operations for at least the next 12 months.
• Revenue for the three months ended June 30, 2026, was $0.7 million, a decrease from $6.3 million in the same period of 2025, primarily due to changes in royalty and licensing agreements.
• Research and development expenses increased to $10.0 million for the three months ended June 30, 2026, from $6.5 million in the prior year period, driven by advancements in OV329 and OV4071 programs.
• General and administrative expenses also increased to $6.5 million for the three months ended June 30, 2026, from $4.9 million in the prior year period, attributed to higher professional fees and increased headcount.
• The company completed private placements in October 2025 and March 2026, raising significant capital, and has an active at-the-market (ATM) program.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant operating losses, a substantial accumulated deficit, and continued reliance on external funding, despite progress in some development areas.

Positives

• Secured substantial capital through private placements in October 2025 ($75.1 million net proceeds) and March 2026 ($56.2 million net proceeds).
• Maintains a significant cash balance of $169.8 million as of June 30, 2026, providing at least 12 months of operational runway.
• Continued progress in advancing lead programs OV329 and OV4071, with increased R&D spending reflecting this.
• The company has no long-term debt as of June 30, 2026.

Negatives

• Reported a net loss of $15.0 million for the quarter and $32.0 million for the six months ended June 30, 2026.
• Accumulated deficit stands at $353.7 million as of June 30, 2026.
• Revenue significantly decreased to $0.7 million for the three months ended June 30, 2026, compared to $6.3 million in the prior year period.
• Operating expenses increased in both R&D and G&A categories.
• The company expects to continue incurring substantial operating losses for at least the next several years.
• High dependence on future capital raises to fund operations.

Risks

• Need for additional capital to finance operations, with no guarantee of availability on acceptable terms.
• Continued substantial operating losses and the possibility of never achieving profitability.
• Early stage of drug development for current candidates, with inherent uncertainty in clinical success and regulatory approval.
• Potential for adverse side effects or properties of drug candidates that could delay or prevent approval.
• Market acceptance of drug candidates, if approved, is not guaranteed.
• Reliance on third parties for manufacturing and clinical trial conduct.
• Potential limitations on the use of Net Operating Loss (NOL) carryforwards due to ownership changes.
• Volatility in the market price of common stock.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for at least the next several years. Its ability to fund operations is dependent on securing additional capital through equity offerings, debt financings, collaborations, or strategic alliances. Management believes current cash, cash equivalents, and marketable securities are sufficient for at least the next 12 months.

Management Comments

• "Our operations have consumed substantial amounts of cash since our inception, primarily due to research and development of our drug candidates, organizing and staffing our company, business planning, raising capital, and acquiring assets."
• "We expect to continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability."
• "We believe that our cash, cash equivalents and marketable securities as of June 30, 2026, will be sufficient to fund our operating and capital expenditure requirements through at least 12 months from the issuance of our unaudited interim condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q."

Industry Context

StockSavvy.ai notes that Ovid Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical sector, focusing on early-stage drug development for brain disorders. The company's financial performance, characterized by significant R&D expenses and net losses, is typical for companies at this stage, with a strong reliance on external financing to advance its pipeline.

Comparison to Industry Standards

• Biopharmaceutical companies in early-stage development typically incur substantial operating losses and require significant external funding, aligning with Ovid's financial profile.
• The increased R&D spending reflects a common strategy to advance promising drug candidates through clinical trials, a standard practice in the industry.
• The reliance on capital raises (private placements, ATM programs) is a standard financing method for biotech firms to manage cash burn during development phases.

Legal Proceedings

• The company is not currently involved in any material legal matters arising in the normal course of business.

Related Party Transactions

• In the 2025 Private Placement, Dr. Jeremy M. Levin, the Company's Executive Chair, purchased shares of Series B Preferred Stock and warrants.
• Dr. Levin exercised Series A Warrants on March 24, 2026.
• In May 2026, Dr. Levin was appointed as chair of the NewCo board of directors, a company formed with Takeda for soticlestat commercialization.

Stakeholder Impact

• Shareholders may experience dilution if additional equity is issued.
• The company's continued reliance on external funding and ongoing losses may impact investor confidence.
• Employees' job security is tied to the company's ability to secure future funding and achieve development milestones.

Next Steps

• Continue advancing drug candidates OV329 and OV4071 through preclinical and clinical development.
• Seek additional sources of funding through equity offerings, debt financings, collaborations, or strategic alliances.
• Manage operating expenses and cash runway to ensure sufficient funding for at least the next 12 months.
• Potentially pursue additional drug candidates through discovery, development, acquisition, or in-licensing.

Key Dates

Recommendation

Ovid Therapeutics shows progress in advancing its pipeline with increased R&D spending, but the significant operating losses, substantial accumulated deficit, and declining revenue present considerable risks. While recent capital raises provide a runway, the company's future success remains highly dependent on securing further funding and achieving clinical and regulatory milestones. Given the speculative nature of early-stage biopharma and the current financial performance, a 'hold' recommendation is appropriate, pending clearer signs of de-risking in the pipeline and improved financial stability.

Keywords

biopharmaceutical, drug development, neurological disorders, clinical trials, OV329, OV4071, capital raise, operating loss